A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Study Identifier
CN-BIM-1102
CT.gov Identifier
NCT02020512
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • 0.03% Bimatoprost
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of open-angle glaucoma or ocular hypertension * No use of Lumigan® in the past 3 months
    Exclusion Criteria:
    * Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months

    Protocol Summary

    This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

    Study Locations

    Location
    Status
    Location
    Guangzhou, China
    Status
    Not applicable